| $385M | ||
| $337M | ||
| $100M | ||
| $87M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $998,237 | 10 | 100 |
| BURKE WILLIAM W | director | 0 | $0 | 1 | $31,911 | $-31,911 |
| Birkemeyer Elaine M. | Chief Financial Officer | 0 | $0 | 3 | $114,555 | $-114,555 |
| Dodd Sheri Louise | Chief Executive Officer | 0 | $0 | 2 | $126,862 | $-126,862 |
| Burns Kristie | Sr. VP Mktg & Clinical Affairs | 0 | $0 | 2 | $163,913 | $-163,913 |
| REUVERS DANIEL L. | director | 0 | $0 | 2 | $560,997 | $-560,997 |
Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers; and AffloVest, a portable high frequency chest wall oscillation test for the treatment of retained pulmonary secretions such as bronchiectasis, cystic fibrosis, and various neuromuscular disorders. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
Over the last 12 months, insiders at Tactile Systems Technology, Inc. have bought $0 and sold $998,237 worth of Tactile Systems Technology, Inc. stock.
On average, over the past 5 years, insiders at Tactile Systems Technology, Inc. have bought $44,835 and sold $556,492 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4,900 shares for transaction amount of $44,835 was made by BURKE WILLIAM W () on 2022‑08‑04.
| 2025-08-08 | Sale | Dodd Sheri Louise | Chief Executive Officer | 7,762 0.035% | $12.36 | $95,907 | +18.73% | |
| 2025-05-12 | Sale | Birkemeyer Elaine M. | Chief Financial Officer | 2,921 0.0128% | $9.94 | $29,037 | +34.52% | |
| 2025-05-08 | Sale | Dodd Sheri Louise | Chief Executive Officer | 3,149 0.0137% | $9.83 | $30,955 | +33.61% | |
| 2025-05-08 | Sale | BURKE WILLIAM W | director | 3,300 0.0141% | $9.67 | $31,911 | +33.61% | |
| 2025-02-25 | Sale | REUVERS DANIEL L. | director | 28,338 0.1132% | $14.18 | $401,850 | -8.41% | |
| 2025-02-25 | Sale | Birkemeyer Elaine M. | Chief Financial Officer | 2,066 0.0084% | $14.51 | $29,980 | -8.41% | |
| 2025-02-25 | Sale | Burns Kristie | Sr. VP Mktg & Clinical Affairs | 6,468 0.0262% | $14.40 | $93,160 | -8.41% | |
| 2025-02-24 | Sale | REUVERS DANIEL L. | director | 10,938 0.0448% | $14.55 | $159,147 | -10.10% | |
| 2025-02-24 | Sale | Birkemeyer Elaine M. | Chief Financial Officer | 3,778 0.0156% | $14.70 | $55,538 | -10.10% | |
| 2025-02-24 | Sale | Burns Kristie | Sr. VP Mktg & Clinical Affairs | 4,830 0.0199% | $14.65 | $70,753 | -10.10% | |
| 2024-08-12 | Sale | Ferstler Sherri Lee | Senior VP, Sales | 1,550 0.0065% | $13.07 | $20,263 | +7.02% | |
| 2024-05-16 | Sale | Birkemeyer Elaine M. | Chief Financial Officer | 3,041 0.0129% | $13.68 | $41,590 | +1.61% | |
| 2024-05-08 | Sale | BURKE WILLIAM W | director | 2,500 0.0107% | $14.06 | $35,150 | +0.40% | |
| 2024-05-06 | Sale | Burns Kristie | Sr. VP Mktg & Clinical Affairs | 815 0.0035% | $14.37 | $11,713 | -1.94% | |
| 2024-02-29 | Sale | REUVERS DANIEL L. | President and CEO | 1,396 0.0059% | $15.25 | $21,289 | -5.70% | |
| 2024-02-29 | Sale | Burns Kristie | Sr. VP Mktg & Clinical Affairs | 243 0.001% | $15.25 | $3,706 | -5.70% | |
| 2024-02-27 | Sale | REUVERS DANIEL L. | President and CEO | 4,689 0.0196% | $15.60 | $73,148 | -9.96% | |
| 2024-02-27 | Sale | Burns Kristie | Sr. VP Mktg & Clinical Affairs | 1,091 0.0045% | $15.58 | $17,001 | -9.96% | |
| 2024-02-26 | Sale | REUVERS DANIEL L. | President and CEO | 6,239 0.0269% | $15.81 | $98,645 | -7.22% | |
| 2024-02-26 | Sale | Burns Kristie | Sr. VP Mktg & Clinical Affairs | 2,015 0.0087% | $15.90 | $32,049 | -7.22% |
| REUVERS DANIEL L. | director | 214604 0.9608% | $5.99M | 0 | 13 | |
| Dodd Sheri Louise | Chief Executive Officer | 173479 0.7767% | $4.84M | 0 | 2 | |
| Birkemeyer Elaine M. | Chief Financial Officer | 99111 0.4437% | $2.77M | 0 | 4 | |
| Burns Kristie | Sr. VP Mktg & Clinical Affairs | 77540 0.3472% | $2.16M | 0 | 11 | |
| BURKE WILLIAM W | director | 48520 0.2172% | $1.35M | 1 | 15 | +42.19% |
| Galen Partners V LP | 10 percent owner | 907736 4.0641% | $25.33M | 0 | 6 | |
| SODERBERG PETER H | director | 236450 1.0586% | $6.6M | 1 | 0 | +38.26% |
| Mattys Gerald R. | Chief Executive Officer | 231784 1.0377% | $6.47M | 0 | 27 | |
| Folkes Robert J. | Chief Operating Officer | 76303 0.3416% | $2.13M | 0 | 75 | |
| Radius Venture Partners III, LLC | 10 percent owner | 75396 0.3376% | $2.1M | 0 | 1 | |
| Anderson Mary E. | Vice President, Reimbursement | 59555 0.2666% | $1.66M | 0 | 11 | |
| Davis Jordan | director | 57316 0.2566% | $1.6M | 0 | 7 | |
| Blake Lynn Larson | Chief Financial Officer | 55004 0.2463% | $1.54M | 0 | 8 | |
| Moen Brent | Chief Financial Officer | 48760 0.2183% | $1.36M | 1 | 9 | <0.0001% |
| Ferstler Sherri Lee | Senior VP, Sales | 38764 0.1736% | $1.08M | 0 | 1 | |
| Rishe Bryan | SVP, Sales | 37567 0.1682% | $1.05M | 0 | 66 | |
| ROCHE KEVIN H | director | 35311 0.1581% | $985,530.01 | 0 | 14 | |
| SHAPIRO STEPHEN I | director | 32460 0.1453% | $905,958.60 | 0 | 1 | |
| PAULS ERIC | Senior VP, Sales | 29498 0.1321% | $823,289.18 | 0 | 4 | |
| NIGON RICHARD | director | 16785 0.0751% | $468,469.35 | 3 | 5 | +21.69% |
| Thompson Maggie | SVP, Reimb. & Payer Relations | 11553 0.0517% | $322,444.23 | 0 | 10 | |
| Pegus Cheryl | director | 2184 0.0098% | $60,955.44 | 1 | 0 | +77.98% |
| Increased Positions | 66 | +46.81% | 1M | +5.43% |
| Decreased Positions | 60 | -42.55% | 2M | -9% |
| New Positions | 16 | New | 201,063 | New |
| Sold Out Positions | 17 | Sold Out | 772,909 | Sold Out |
| Total Postitions | 147 | +4.26% | 21M | -3.57% |
| Morgan Stanley | $58,956.00 | 10.42% | 2.29M | +1,569 | +0.07% | 2025-09-30 |
| Cadian Capital Management, Lp | $52,854.00 | 9.34% | 2.06M | -253,858 | -10.99% | 2025-09-30 |
| Blackrock, Inc. | $45,438.00 | 8.03% | 1.77M | -5,572 | -0.31% | 2025-09-30 |
| Vanguard Group Inc | $40,493.00 | 7.16% | 1.57M | +44,218 | +2.89% | 2025-09-30 |
| Paradigm Capital Management Inc/Ny | $39,552.00 | 6.99% | 1.54M | -80,200 | -4.96% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $30,626.00 | 5.42% | 1.19M | +24,001 | +2.06% | 2025-09-30 |
| Capitolis Liquid Global Markets Llc | $23,192.00 | 4.1% | 902,062 | 0 | 0% | 2025-09-30 |
| Acadian Asset Management Llc | $21,736.00 | 3.84% | 845,448 | +161,786 | +23.66% | 2025-09-30 |
| Nuveen Asset Management, Llc | $17,432.00 | 3.08% | 678,026 | -207,186 | -23.41% | 2024-12-31 |
| Deutsche Bank Ag | $14,839.00 | 2.62% | 577,187 | -41,700 | -6.74% | 2025-09-30 |